Navigation Links
Latinas more likely to regret breast cancer treatment decisions
Date:11/17/2008

ANN ARBOR, Mich. Latina women who prefer speaking Spanish are more likely than other ethnic groups to express regret or dissatisfaction with their breast cancer treatment, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.

Despite receiving similar treatment, Latina women were 5.6 times more likely than white women to report high levels of dissatisfaction and regret about their breast cancer treatment decision.

The researchers found that Latinas and other ethnic groups had similar levels of involvement with their doctor in deciding the treatment plan. But Latinas were more likely to say they would have preferred to be more involved in the decision making.

Researchers surveyed 925 women with non-advanced breast cancer from the Los Angeles area. Women were asked about the decision making process in choosing their breast cancer treatment. Nearly half of the women surveyed were Latina, with a quarter preferring to speak Spanish. These women were 3.5 times more likely than English-speaking Latinas to have difficulty understanding written information about breast cancer.

"Even though they received similar amounts of information as whites, Latinas who prefer speaking Spanish reported a strong desire for more information. Doctors may need to make additional effort to ensure this information is understandable and culturally appropriate for all ethnic groups to improve the decision making process for breast cancer patients," says lead study author Sarah T. Hawley, Ph.D., assistant professor of internal medicine at the U-M Medical School and a research investigator at the VA Ann Arbor Healthcare System.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1

Related medicine news :

1. Sense of personal control influences Latinas decisions about sexual debut
2. Wealthy More Likely to Have Breast Reconstruction
3. Bottoms up: Individualists more likely to be problem drinkers
4. New Survey Indicates "Highest-Value" Physicians Most Likely to Participate in Aptilons Live Video Detailing Service
5. Hispanics Less Likely to Get Repeat Artery Surgery
6. Hispanics less likely to have repeat revascularizations 1 year after angioplasty
7. Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation
8. Smokers Homes More Likely to House Hungry Kids
9. Wait time guarantees not likely to reduce waits for joint replacement surgery
10. Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?
11. Minorities More Likely to Die in ER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...one of 63 businesses honored in Washington, D.C. ...wire/ -- Texas Health Resources has received the...m the National Business Group on Health. , , (L...02/DC41773LOGO ) , , The award recognizes th...grams that promote a healthy workplace and for hel...
(Date:7/2/2009)...ight problems faced by youngsters with the disease...- Children with type 1 diabetes are more likely to...reasing their risk of serious health complications...r study that explored the weight problems faced by...on form of the disease that usually shows up in ch...
(Date:7/2/2009)...ical and biological issues need to be addressed in...ly detection of cancer, according to a commentary ...ional Cancer Institute . , The biomarker pipelin...ncludes the identification of promising biomarkers...itive evaluation of biomarkers for cancer screenin...
(Date:7/2/2009)... patients who receive brachytherapy and remain fre...y to have a recurrence at 10 years, according to a...ournal of Radiation Oncology*Biology*Physics , the...ation Oncology (ASTRO)., Brachytherapy is the pla... tumor either permanently or temporarily, dependin...
Breaking Medicine News(10 mins):Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Kids With Type 1 Diabetes Often Overweight 2
...od and Drug Administration has avowed Biolase Tech... vend its Waterlase laser therapy for root canal p...s the first by the FDA for a laser root canal and ...as well as shaping of the root canal. The Waterlas...
... is on the way for longtime sufferers. New researc...ntidepressants and stress-management training can ...of chronic tension headches, which strike millions...th mild to moderate head pain that occurs more tha...
...chers from the university of Michigan state that W... percent more likely than nonsmokers to give birth...of the birth defect rises with the number of cigar...fter factors like the mother's race, age and educa...
...ch says that giving extra radiotherapy to patients...e risk of cancer recurring in the breast. //The re...be changed immediately, particularly for younger w...ook part in the study. The majority of patients ha...
Other Medicine News:
(Date:6/29/2009)...minal surgery patients achieved primary and second... AcelRx Pharmaceuticals, Inc. toda... 2 clinical study evaluating the safety and effica...anagement of acute post-operative pain in patients.... Compared to placebo, patients receiving ARX-01 S...
(Date:6/28/2009)...land and TOKYO, June 29 , -...s , Sosei Group Corporation ("Sosei"; TSE M...ra"; LSE: VEC) announce the commencement of a Phas...once-daily, long-acting muscarinic,antagonist (LA...nary disease,(COPD). NVA237 is a dry powder formu...
(Date:6/26/2009)...commends Approval of New Anti-TNF Therapy in Three...njector , , HORSHAM, Pa. and KENILWORTH, N.J., ...iotech Inc. and Schering-Plough Corporation (NYSE:...dicinal Products for Human Use (CHMP) of the Europ...nion recommending the approval of SIMPONI(TM) (gol...
(Date:6/25/2009)...A (TM) Data Highlighted at the College on Problems...v., June 25 King Pharmaceuticals...any is presenting safety and efficacy data for ACU... analgesic formulations that are in development, a...ms of Drug Dependence. King is also developing ot...
Breaking Medicine Technology:AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6Viral Therapy Slows Pediatric Tumors in Mice 12024 1Viral Therapy Slows Pediatric Tumors in Mice 12024 2Milestone Scientific to Exhibit at the Chicago Dental Societys 143rd Midwinter Meeting 12022 1Milestone Scientific to Exhibit at the Chicago Dental Societys 143rd Midwinter Meeting 12022 2Milestone Scientific to Exhibit at the Chicago Dental Societys 143rd Midwinter Meeting 12022 3KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 1KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 2KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 3KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 4KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 5KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 6KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 7KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 8KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 9KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 10KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 11KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 12KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 13KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 14KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 15KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 16KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 17KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 18KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 19KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 20KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 21KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 22KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 23Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 1Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 2Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 3Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 4Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 5Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 6Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 7Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 8
... Hypertension,Treatment Valsartan in Preventing Ca...pril 26, 2007 /Xinhua-PRNewswire/ -- The clinical,... clinical trial,headed by the Jikei University Sch...ationally renowned medical journal The,Lancet. The... of,the largest cardiovascular intervention trials...
...,Merck Serono S.A. (virt-x: SEO) and its partner N... today that Professor,Fabrizio Stocchi, MD, PhD, w...al of safinamide as an adjunctive treatment to,dop...ease (PD),patients at the American Academy of Neur...m 28 April to 5 May 2007. , The abstract entitled ...
Other Medicine Technology:First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 2First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 3First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 4Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 2Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 3Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 4
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: